{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-26-000048","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2026-10-13T10:19:25+00:00","discovered_at":"2026-10-13T10:20:00.254777+00:00","generated_at":"2026-10-13T10:20:09.192937+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nurix Q3 FY26 revenue $673.1M on Roche collaboration; net income $549.8M, EPS $4.73","bullets":["Revenue $673.1M vs $7.9M YoY, including $653.2M license revenue from Roche and a $10.0M Sanofi milestone.","Net income $549.8M, or $4.73 per diluted share, vs an $86.4M net loss (-$1.03) a year ago; cash $1.1B with runway into H2 2029.","Dosed first patient in Phase 3 DAYBreak CLL-306 testing bexobrutideg 600 mg vs pirtobrutinib in ~620 relapsed/refractory CLL/SLL patients; dual primary endpoints ORR and PFS.","Phase 1a CLL data showed median PFS 22.1 months and 83.0% ORR; Phase 1b ORR 92.9% in BTK-pretreated/BCL2-naive patients.","Discontinued NX-2127; NX-1607 entered Phase 1b in MSS CRC, NSCLC, CRPC and melanoma; Gilead extended a research term for a $10.0M fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-26-000048","json":"https://secwatch.observer/filing/0001549595-26-000048.json","markdown":"https://secwatch.observer/filing/0001549595-26-000048.md","text":"https://secwatch.observer/filing/0001549595-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/0001549595-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/nrix-20261012.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T10:20:09.192937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}